본문 바로가기
KERD
논문KCI 등재

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma

유은실|김기훈|김승미|김태원|임영석|이한주|정영화|이용상|강효정|심주현|김강모|이효정
대한간학회 (The korean Association for the Study of the Liver)|2015.03|Clinical and Molecular Hepatology|제21권 제1호|pp. 60-70

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ImmunohistochemistrySurvivalHepatocellular carcinomaReceptorFibroblast growth factor

초록

Background/Aims: Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study wasto determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) andneighboring nonneoplastic liver tissue, and elucidate its prognostic implications. Methods: Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboringnonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patientswho underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotypeexpression and overall survival was evaluated (development set). This association was also validated in 73 independentsamples (validation set) by Western blot analysis. Results: FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among thedevelopment set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-yearsurvival rate, 35.3% vs. 61.8%; P =0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgicalprognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statisticallysignificant in the validation set. Conclusions: FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival. (Clin Mol Hepatol2015;21:60-70)

Abstract

Background/Aims: Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study wasto determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) andneighboring nonneoplastic liver tissue, and elucidate its prognostic implications. Methods: Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboringnonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patientswho underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotypeexpression and overall survival was evaluated (development set). This association was also validated in 73 independentsamples (validation set) by Western blot analysis. Results: FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among thedevelopment set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-yearsurvival rate, 35.3% vs. 61.8%; P =0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgicalprognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statisticallysignificant in the validation set. Conclusions: FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival. (Clin Mol Hepatol2015;21:60-70)

참고문헌 (34)

  1. Llovet JM, "Hepatocellular carcinoma", The Lancet, 362, pp.1907~1917 (2003)
  2. Sherman M, "Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis", Semin Liver Dis, 30, pp.3~16 (2010)
  3. Ho CM, "Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy : Comparative effectiveness of treatment modalities", Surgery, 5, pp.700~709 (2012)
  4. Zhong JH, "Adjuvant therapy options following curative treatment of hepatocellular carcinoma : A systematic review of randomized trials", Eur J Surg Oncol, 38, pp.286~295 (2012)
  5. Llovet JM, "Natural history of untreated nonsurgical hepatocellular carcinoma : Rationale for the design and evaluation of therapeutic trials", Hepatology, 29, pp.62~67 (1999)
  6. Natsuizaka M, "Clinical features of hepatocellular carcinoma with extrahepatic metastases", J Gastroenterol Hepatol, 20, pp.1781~1787 (2005)
  7. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
  8. Llovet JM, "Molecular targeted therapies in hepatocellular carcinoma", Hepatology, 48, pp.1312~1327 (2008)
  9. Turner N, "Fibroblast growth factor signalling : From development to cancer", Nat Rev Cancer, 10, pp.116~129 (2010)
  10. Amann T, "Reduced expression of fibroblast growth factor receptor 2iiib in hepatocellular carcinoma induces a more aggressive growth", Am J Pathol, 176, pp.1433~1442 (2010)
  11. Harimoto N, "The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma", Oncology, 78, pp.361~368 (2010)
  12. Ho HK, "Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alphafetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention", J Hepatol, 50, pp.118~127 (2009)
  13. Huang X, "Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis", Mol Carcinog, 48, pp.553~562 (2009)
  14. Gauglhofer C, "Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis", Hepatology, 53, pp.854~864 (2011)
  15. Kwabi-Addo B, "The role of fibroblast growth factors and their receptors in prostate cancer", Endocr Relat Cancer, 11, pp.709~724 (2004)
  16. Grose R, "Fibroblast growth factor signaling in tumorigenesis", Cytokine Growth Factor Rev, 16, pp.179~186 (2005)
  17. Ingersoll RG, "Fibroblast growth factor receptor 2(fgfr2) : Genomic sequence and variations", Cytogenet Cell Genet, 94, pp.121~126 (2001)
  18. Mas VR, "Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis c virus cirrhotic patients awaiting liver transplantation", Transplantation, 84, pp.1262~1271 (2007)
  19. Katoh M, "Cancer genomics and genetics of fgfr2(review)", Int J Oncol, 33, pp.233~237 (2008)
  20. Adnane J, "Bek and flg, two receptors to members of the fgf family, are amplified in subsets of human breast cancers", Oncogene, 6, pp.659~663 (1991)
  21. Katoh M, "Fgf signaling network in the gastrointestinal tract(review)", Int J Oncol, 29, pp.163~168 (2006)
  22. Kan M, "Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase", J Biol Chem, 274, pp.15947~15952 (1999)
  23. Hu Z, "Expression of fibroblast growth factor receptors flg and bek during hepatic ontogenesis and regeneration in the rat", Cell Growth Differ, 6, pp.1019~1025 (1995)
  24. Hu Z, "Expression of transforming growth factor alpha", epidermal growth factor receptor, hepatocyte growth factor, fibroblast growth factor receptors during hepatocarcinogenesis, pp.Carcinogenesis, 1996[DOI]
  25. Miura S, "Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma", BMC Cancer, 12, pp.56~ (2012)
  26. Desnoyers LR, "Targeting fgf19 inhibits tumor growth in colon cancer xenograft and fgf19transgenic hepatocellular carcinoma models", Oncogene, 27, pp.85~97 (2008)
  27. Luo Y, "Metabolic regulator betaklotho interacts with fibroblast growth factor receptor 4(fgfr4)to induce apoptosis and inhibit tumor cell proliferation", J Biol Chem, 285, pp.30069~30078 (2010)
  28. Huang X, "Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis", Cancer Res, 66, pp.1481~1490 (2006)
  29. Sasaki S, "Interferon-alpha", beta and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo, 2011, pp.6, e19618~
  30. Wang J, "Downregulation of microrna-214and overexpression of fgfr-1 contribute to hepatocellular carcinoma metastasis", Biochem Biophys Res Commun, 439, pp.47~53 (2013)
  31. Kanai M, "Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kda phosphoprotein", J Biol Chem, 272, pp.6621~6628 (1997)
  32. Qiu WH, "Overexpression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma", World J Gastroenterol, 11, pp.5266~5272 (2005)
  33. Bataller R, "Liver fibrosis", J Clin Invest, 115, pp.209~218 (2005)
  34. Gressner AM, "Modern pathogenetic concepts of liver fibrosis suggest stellate cells and tgf-beta as major players and therapeutic targets", J Cell Mol Med, 10, pp.76~99 (2006)

이 간행물의 다른 논문 (7건)

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir조형호, 최한나, 이현철, 송정은, 김병석, 이창형pp. 24-31The factor that improve liver stiffness in patients with chronic hepatitis BIn Sik Won, 박평화, 장필규, sun young na, 이정현, 김주현, 김윤수, 권오상, 박진웅, 최덕주, 여인구, Jong Joon Leepp. 32-40Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patientsBu Hyun Lee, Hyun Kyo Lee, So Young Ha, 김경아, 정상경, 이준성, Nam-Hoon Kim, 백우현, Jong Wook Kim, Won Ki Bae, Yoon Jung Jwa, Young Doo Kimpp. 41-48Combined treatment of silibinin with either sorafenib or EGFR tyrosine kinase inhibitors enhances growth inhibitory effects in hepatocellular carcinoma cellsJae Cheol Lee, Jae-Hoon Jeong, Su Jin Choi, 김연주, Ha Ra Gu, Su Cheol Park, You Cheoul Kim, Chul Ju Han, Ki Young Yang, Geum Youb Noh, So Hyeon Nopp. 49-59Alteration of Laboratory Findings after Radiofrequency Ablation of Hepatocellular Carcinoma: The Relationship with Severity of Underlying Liver Diseases and Ablation Volume김진우, 정우경, 임상혁, 신상욱, 김용수pp. 71-89
원문 보기